Aarti Drugs Q2 Results: Margin Recovery Gains Momentum, What's Ahead?

Aarti Drugs delivers a steady Q2 performance, marking signs of a margin recovery and stronger export momentum. Revenue rose 9% YoY to ₹653 crore, while PAT surged 29% to ₹45 crore. EBITDA grew 26% YoY to ₹84.3 crore, with margins improving by 150 bps to 12.9%. APIs remained the key revenue driver at 79%, followed by formulations and specialty chemicals. The company’s focus on onco-therapy exports and cost optimization signals a positive turnaround ahead. With a market cap of ₹4,332 crore and promoter holding at 54.7%, Aarti Drugs is betting on export growth and product diversification to sustain profitability in coming quarters. The road ahead looks promising for this pharma midcap on the comeback trail.